The global human insulin market size is anticipated to reach USD 27.71 billion by 2026. International Diabetes Federation (IDF) reported that around 425 million people across the world suffer from diabetes. This shows that the rising prevalence of diabetes is propelling growth in the market. Fortune Business Insights in a new report, titled “Human Insulin Market Size, Share & Industry Analysis, By Type (Analogue Insulin (Long-Acting, Fast Acting, Premix), Traditional Human Insulin (Long-Acting, Short-Acting, Fast Acting, Premix)), By Diabetes Type (Type 1, Type 2), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), and Regional Forecast, 2019-2026” predicts the market to exhibit a CAGR of 3.4% during the forecast period. In 2018, the market value stood at USD 21.26 billion in 2018. The adoption of delivery devices primarily for insulin administration is increasing, thus driving the market.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/human-insulin-market-100395
Leading Players operating in the Human Insulin Market are:
Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:
- Novo Nordisk A/S
- Eli Lilly and Company
- Boston Scientific Corporation
- Sanofi
- Boehringer Ingelheim International GmbH
- Biocon
- Tonghua Dongbao Pharmaceutical
- Julphar
- Wockhard
- Other prominent players
Eli Lilly & Company to Launch Analogue Humalog Insulin in the U.S.
Among products, analogue insulin covered the maximum part in the human insulin market share in 2018. Analogue insulin helps to control blood sugar levels in people suffering from type 1 and type 2 diabetes. Driven by this, the adoption of analogue insulin is increasing, which increases the human insulin market size. This, coupled with the recent launch of generic insulin, is expected to contribute to the growth of the market. For instance, Eli Lilly and Company announced the launch of a generic version of analogue Humalog insulin called Insulin Lispro in April 2019. Owing to the cheaper rates of Humalog, this insulin is more accessible to diabetic patients in the country. This segment is expected to drive the human insulin market in the foreseeable future.
Detailed Table of Content:
- Introduction
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- Prevalence of Diabetes – Key Countries
- Pipeline Analysis
- Brand Analysis
- Key Market Strategies of Leading Players
- Overview of Regulatory Scenario – Key Countries
- Global Human Insulin Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Type
- Analogue Insulin
- Long-acting
- Fast-acting
- Premix
-
-
- Traditional Human Insulin
-
- Long-acting
- Short-acting
- Fast-acting
-
-
-
- Premix
-
- Market Analysis, Insights and Forecast – By Diabetes Type
- Diabetes Type 1
- Diabetes Type 2
- Market Analysis, Insights and Forecast – By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Market Analysis, Insights and Forecast – By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
-
Human Insulin Market Segmentation:
By Type
- Analogue Insulin
- Long-acting
- Fast-acting
- Premix
- Traditional Human Insulin
- Long-acting
- Short-acting
- Fast-acting
- Premix
By Diabetes Type
- Diabetes Type 1
- Diabetes Type 2
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Geography
- North America (U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
- Latin America (Brazil, Mexico, and Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Reasons to Purchase this Report:
- Comprehensive analysis of the Human Insulin Market growth drivers, obstacles, opportunities, and other related challenges.
- Tracks the developments, such as new product launches, agreements, mergers and acquisitions, geographical expansions, and joint ventures.
- Identifies market restraints and boosters.
- Identifies all the possible segments present in the market to aid organizations in strategic business planning.
Have Any Query? Ask Our Experts:https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/human-insulin-market-100395
KEY QUESTIONS ANSWERED:
- What are the key technological and Human Insulin Market trends shaping the market?
- What are the key opportunities in the market?
- What are the key companies operating in the market?
- Which company accounted for the highest market share?
- Why Choose Fortune Business Insights?
- What is the market size and growth rate of the global and regional market by various segments?
- What is the market size and growth rate of the market for selective countries?
- Which region or sub-segment is expected to drive the market in the forecast period?
- What Factors are estimated to drive and restrain the Human Insulin Market growth?
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245